美国 · SEC FORM 4
Kalaris Therapeutics, Inc.
KLRS · Nasdaq · CIK 0001754068 · Healthcare · Biotechnology
内部人信号
1 位买方 · 1 条买入交易行 · $1.2M 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase activity is becoming less recent
- ✓ 角色得分高 · 买入者中职位最高的是：Director,TenPercentOwner; TenPercentOwner
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
买方广度与集中度
Roles in the peak window: Director,TenPercentOwner; TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
最新留档分数
- 56.3
- 56.3
- 56.2
- 56.2
- 56.2
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -28.5%
- 3M
- -46.6%
- 6M
- -62.5%
- 12M
- -64.2%
波动率与流动性
- 波动率
- 99.7%
- Beta
- —
- 平均每日成交额
- USD 607,262
估值
- 市值
- USD 56.2M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -55.1%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-04 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 331,876
- 上期报告
- 318,361
- 日均成交量
- 72,771
- 回补天数
- 4.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P. | 买入 (P) | Common Stock | 244,300 | USD 4.83 | USD 1,179,969 | SEC 申报 ↗ |
| 2025-12-18 | AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P. | 买入 (P) | Common Stock | 479,847 | USD 10.42 | USD 5,000,006 | SEC 申报 ↗ |
| 2023-06-27 | GILEAD SCIENCES, INC. | 买入 (P) | Common Stock | 2,930,870 | USD 3.75 | USD 10,990,762 | SEC 申报 ↗ |
| 2022-04-26 | Bornstein Jeffrey S | 买入 (P) | Common Stock | 5,000 | USD 4.64 | USD 23,200 | SEC 申报 ↗ |
| 2022-02-10 | Bornstein Jeffrey S | 买入 (P) | Common Stock | 5,000 | USD 8.87 | USD 44,350 | SEC 申报 ↗ |
| 2020-08-03 | Jovan-Embiricos Morana | 买入 (P) | Common Stock | 2,900,000 | USD 17.00 | USD 49,300,000 | SEC 申报 ↗ |
| 2020-08-03 | VAN BEEK JEROEN B | 买入 (P) | Common Stock | 3,000 | USD 17.00 | USD 51,000 | SEC 申报 ↗ |
| 2020-08-03 | Brainard Diana | 买入 (P) | Common Stock | 6,300 | USD 17.00 | USD 107,100 | SEC 申报 ↗ |
| 2020-08-03 | Atillasoy Ercem | 买入 (P) | Common Stock | 3,500 | USD 17.00 | USD 59,500 | SEC 申报 ↗ |
Form 4 申报证据
7 transaction lines in the latest 365-day window; 451 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P. | 买入 (P) | Common Stock | 244,300 | USD 4.83 | USD 1,179,969 | SEC 申报 ↗ |
| 2026-05-20 | AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P. | J (J) | Common Stock | 86,314 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-20 | Hagen Brett R | 卖出 (S) | Common Stock | 1,915 | USD 6.72 | USD 12,869 | SEC 申报 ↗ |
展开近期 Form 4 证据 (5 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P. | 买入 (P) | Common Stock | 244,300 | USD 4.83 | USD 1,179,969 | SEC 申报 ↗ |
| 2026-05-20 | AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P. | J (J) | Common Stock | 86,314 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-20 | Hagen Brett R | 卖出 (S) | Common Stock | 1,915 | USD 6.72 | USD 12,869 | SEC 申报 ↗ |
| 2025-12-22 | AKKARAJU SRINIVAS; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P. | 奖励／授予 (A) | Common Stock | 1,500,000 | USD 10.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2025-12-18 | AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P. | 买入 (P) | Common Stock | 479,847 | USD 10.42 | USD 5,000,006 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | KLRS |
| CIK | 0001754068 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 451 transaction lines from 2020-07-29 to 2026-05-20 10 P purchase lines · 345 S sale lines · 96 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.